

**DIABETES PROOF LIMITED**

**Abridged Unaudited Financial Statements  
For the financial year ended  
30 June 2025**

**Registered number 672748**

# DIABETES PROOF LIMITED

---

## ABRIDGED FINANCIAL STATEMENTS

| <i>Contents</i>                   | <b>Page</b> |
|-----------------------------------|-------------|
| Directors and other information   | 3           |
| Balance sheet                     | 4           |
| Notes to the financial statements | 5-9         |

# DIABETES PROOF LIMITED

---

## DIRECTORS AND OTHER INFORMATION AT DATE OF APPROVAL OF FINANCIAL STATEMENTS

|                   |   |
|-------------------|---|
| Director          | Siobhan Dee   |
| Secretary         | Sinead Dee (appointed 1 February 2026)<br>John O'Neill (resigned 1 February 2026)                       |
| Registered office | 11 Grotto Avenue<br>Booterstown<br>Co. Dublin   |
| Accountants       | Pangur Consulting Limited<br>Chartered Accountants<br>Ballycoppigan<br>Borris<br>Co, Carlow<br>R95 PXC2 |

# DIABETES PROOF LIMITED

## NOTES TO THE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 30 June 2025

### BALANCE SHEET AS AT 30 JUNE 2025

|   | Notes | 2025<br>€      | 2024<br>€       |
|---|-------|----------------|-----------------|
| <b>Current Assets</b>                                 |       |                |                 |
| Cash at bank and in hand                              |       | 22,178         | 26,539          |
| Debtors   | 4     | 8,468          | 32,349          |
|   |       | <u>30,646</u>  | <u>58,888</u>   |
| <b>Creditors:</b> Amounts falling due within one year | 5     | <u>(2,436)</u> | <u>(37,287)</u> |
| <b>Net current assets</b>                             |       | <u>28,210</u>  | <u>21,601</u>   |
| <b>Total assets less current liabilities</b>          |       | <u>28,210</u>  | <u>21,601</u>   |
| <b>Net assets</b>                                     |       | <u>28,210</u>  | <u>21,601</u>   |
| <b>Capital and reserves</b>                           |       |                |                 |
| Called up share capital presented as equity           |       | 1              | 1               |
| Profit and loss account                               |       | <u>28,209</u>  | <u>21,600</u>   |
| <b>Shareholders' equity</b>                           |       | <u>28,210</u>  | <u>21,601</u>   |

These financial statements have been prepared in accordance with the Small Companies Regime.

I, as the Director of Diabetes Proof Limited, state that:

- the company is availing itself of audit exemption - the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014;
- the company is availing itself of the exemption on the grounds that Section 358 is complied with;
- no notice under Subsection (1) of Section 334 has, in accordance with Subsection (2) of that section, been served on the company; and
- the director acknowledges the obligations of the company, under the Companies Act 2014 to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for that financial year, and otherwise comply with the provisions of the Companies Act 2014 relating to financial statements so far as they are applicable to the company.

In preparing these abridged financial statements, the directors have relied on the exemption contained in section 352 of the Companies Act 2014 on the ground that the company is a small company and qualifies for the small companies regime and is entitled to the benefit of that exemption. These abridged financial statements have been properly prepared in accordance with section 353 of the Companies Act 2014.

Approved by the board of directors and signed on its behalf by

Siobhan Dee  
Director



5 February 2026

# DIABETES PROOF LIMITED

## NOTES TO THE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 30 June 2025

---

### 1. General Information

The financial statements comprising the Profit and Loss Account, the Balance Sheet and the related notes constitute the individual financial statements of Diabetes Proof Limited for the financial year ended 30 June 2025.

Diabetes Proof Limited is a private company limited by shares (registered under Part 2 of Companies Act 2014), incorporated and registered in the Republic of Ireland. The Registered Office is 11 Grotto Avenue, Booterstown, Co. Dublin, which is also the principal place of business of the company. The nature of the company's operations and its principal activities are set out in the Director's Report.

### 2. Statement of Compliance

The financial statements have been prepared in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" (FRS 102), applying section 1A of that Standard.

### 3. Summary of Significant Accounting Policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.

#### **Basis of preparation**

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention modified to include certain items at fair value. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 (the Act) and FRS 102 *The Financial Reporting Standard applicable in the UK and Republic of Ireland* issued by the Financial Reporting Council. The company qualifies as a small company for the period, as defined by section 280A of the Act, in respect of the financial year, and has applied the rules of the 'Small Companies Regime' in accordance with section 280C of the Act and Section 1A of FRS 102.

#### **Turnover**

Turnover is measured at the fair value of the consideration received or receivable for goods supplied and services rendered, net of discounts and Value Added Tax.

#### **Government grants**

Grants are recognised at fair value of the asset receivable using the accruals model when there is reasonable assurance that the grant will be received and all attaching conditions will be complied with. Grants towards capital expenditure are credited to deferred income and are released to the profit and loss account over the expected useful life of the related assets, by equal annual instalments. Grants towards revenue expenditure are released to the profit and loss account as the related expenditure is incurred.

# DIABETES PROOF LIMITED

## NOTES TO THE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 30 June 2025

---

### **Dividends**

Dividends to the company's equity shareholders are recognised as a liability of the company when approved by the company's shareholders.

### **Short term employee benefits**

Short term benefits, including holiday pay, are recognised as an expense in the period in which employees have become entitled to the benefits as a result of service rendered to the company.

### **Taxation and deferred taxation**

The charge for taxation is based on the profit for the financial year and is calculated with reference to the tax rates applying at the financial year end date in the jurisdiction where the tax is applied. Deferred taxation is calculated on the differences between the company's taxable profits and the results as stated in the financial statements that arise from the inclusion of gains and losses in tax assessments in periods different from those in which they are recognised in the financial statements. Full provision for deferred tax assets and liabilities is made at current tax rates on differences that arise between the recognition of gains and losses in the financial statements and their recognition in the tax computation, including differences arising on the revaluation of fixed assets. Deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

### **Foreign currencies**

Transactions in foreign currencies are recorded at the rate ruling at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated at the rate of exchange ruling at the financial year end date. Non-monetary items that are measured at historical cost are translated at the foreign exchange rate ruling at the date of the transaction. Non-monetary items measured at fair value are translated at the rate of exchange at the date when the fair value was determined. All foreign exchange differences are taken to the profit and loss account.

### **Financial Instruments**

#### ***Ordinary Share Capital***

The ordinary share capital of the company is presented as equity.

#### ***Cash and cash equivalents***

Cash consists of cash on hand and demand deposits. Cash equivalents consist of short term highly liquid investments that are readily convertible to known amounts of cash that are subject to an insignificant risk of change in value.

#### ***Other financial assets***

Other financial assets including trade debtors arising from goods sold to customers on short-term credit, are initially measured at the undiscounted amount of cash receivable from that debtor, which is normally the invoice price. If payment is deferred beyond normal business terms or is financed at a rate of interest

# DIABETES PROOF LIMITED

## NOTES TO THE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 30 June 2025

---

that is not a market rate, this constitutes a financing transaction, and the financial liability is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Subsequently, other financial assets are measured at amortised cost less impairment, where there is objective evidence of impairment.

### ***Loans and borrowings***

All loans made by the company are initially recorded at the amount of cash advanced plus transaction costs incurred, unless the arrangement constitutes, in effect, a financing transaction, in which case it is measured at the present value of future payments discounted at a market rate of interest for a similar debt instrument. Subsequently loans made by the company are stated at amortised cost using the effective interest rate method less impairment, where there is objective evidence of impairment.

All borrowings by the company, with the exception of loans from directors who are natural persons and shareholders in the company (or close members of the family of such persons), are initially recorded at the amount of cash received less separately incurred transaction costs, unless the arrangement constitutes, in effect, a financing transaction, in which case it is measured at the present value of future payments discounted at a market rate of interest for a similar debt instrument. Subsequently, borrowings are stated at amortised cost using the effective interest rate method.

Loans from directors who are natural persons and shareholders in the company (or close members of the family of such persons) are initially measured at transaction price and not discounted on subsequent measurement.

The computation of amortised cost includes any issue costs, transaction costs and fees, and any discount or premium on settlement, and the effect of this is to amortise these amounts over the expected borrowing period. Loans with no stated interest rate and repayable within one year or on demand are not amortised. Loans and borrowings are classified as current assets or liabilities unless the borrower has an unconditional right to defer settlement of the liability for at least twelve months after the financial year end date.

### ***Other financial liabilities***

Other financial liabilities, including trade creditors arising from goods purchased from suppliers on short-term credit, are initially measured at the undiscounted amount owed to the creditor, which is normally the invoice price. Liabilities that are settled within one year are not discounted. If payment is deferred beyond normal business terms or is financed at a rate of interest that is not a market rate, this constitutes a financing transaction, and the financial liability is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Subsequently, other financial liabilities are measured at amortised cost.

### **Impairment of financial assets**

At the end of each reporting period, the company assesses whether there is objective evidence of impairment of any financial assets that are measured at cost or amortised cost, including unlisted

# DIABETES PROOF LIMITED

## NOTES TO THE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 30 June 2025

---

investments, loans, trade debtors and cash. If there is objective evidence of impairment, impairment losses are recognised in the Profit and Loss account in that financial year.

### **JUDGEMENTS**

The director considers the accounting assumptions below to be its critical accounting judgements:

#### ***Going Concern***

The financial statements have been prepared on a going concern basis.

The Director has carefully reviewed the future prospects of the company and its future cash flows, and has a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future being at least the next 12 months from signing of these financial statements.

For this reason, the director continues to adopt the going concern basis for the preparation of the Financial Statements. Accordingly, these financial statements do not include any adjustments to the carrying amount or classification of assets and liabilities that would result if the company was unable to continue as a going concern.

#### **4. Director's remuneration and transactions**

Included in staff costs are the following in respect of the director of the company:

|  | <b>2025</b>          | <b>2024</b>          |
|--|----------------------|----------------------|
|  | <b>€</b>             | <b>€</b>             |
| Emoluments in respect of qualifying services | <b>42,127</b>        | <b>57,794</b>        |
|  | <b><u>42,127</u></b> | <b><u>57,794</u></b> |

There were no other transactions with the director in the year (2024: Nil).

#### **5. Employee numbers**

The average monthly number of persons employed by the company (including executive directors) during the financial year was 1 (2024: 1).

# DIABETES PROOF LIMITED

## NOTES TO THE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 30 June 2025

### 6. Debtors

|                 | 2025         | 2024          |
|-----------------|--------------|---------------|
|                 | €            | €             |
| Trade debtors   | -            | 32,349        |
| VAT             | 6,338        | -             |
| Corporation Tax | 2,130        | -             |
|                 | <u>8,468</u> | <u>32,349</u> |

### 7. Creditors: amounts falling due within one year

|  | 2025         | 2024          |
|--|--------------|---------------|
|  | €            | €             |
| Other creditors including tax and social insurance | -            | 37,287        |
| Director's loan                                    | 2,437        | -             |
|  | <u>2,437</u> | <u>37,287</u> |

### 8. Events after the end of the financial year

There have been no significant events affecting the Company since the year end that require adjustment to or disclosure in these financial statements.

### 9. Related party transactions and controlling party

#### *Ultimate controlling party*

Siobhan Dee, the director of the company, is considered by the director to be the company's ultimate controlling party as she holds 100% (2024: 100%) of the ordinary share capital of the company.

#### *Key management personnel compensation*

The director's remuneration disclosed in note 2 represents the total compensation paid to key management personnel.

#### *Other related party transactions*

There were no other related party transactions requiring disclosure in the financial statements.

### 10. Appropriation of profit and loss account

|   | 2025          | 2024          |
|---|---------------|---------------|
|   | €             | €             |
| Profit brought forward at the beginning of the financial year | 21,600        | -             |
| Profit for the financial year                                 | 6,609         | 21,600        |
|   | <u>28,209</u> | <u>21,600</u> |